price month
competitor data ada underwhelm
support bullish novo view
updat ada support bullish novo stanc reiter
outperform rate price target make chang
forecast global american diabet associ ada annual
meet note- lilli weekend updat ada somewhat underwhelm
includ note novo analyst meet
lilli toler data dual glp/gip remain concern head
ada novo investor nervou lilli could improv upon prior
toler concern glp/gip tirzepatid titrat data ada
across new titrat regimen show improv gi side-effect
still meaning rate nausea vomit diarrhea
lilli utilis even slower titrat schedul phase
surpass program toler profil continu improv
larg degre titrat could limit use primari care set view
rewind data support broader usag headlin trulic data
show rel reduct composit mace endpoint
line prior cv outcom studi although patient includ
rewind lower risk cv event believ rewind data
lilli build share voic help grow market
echo lancet editori data ultim see driver
use remain reduct weight loss rather cv benefit
ozemp demonstr superior
catalyst risk start soul cv outcom studi
semaglutid phase tripl data oral sema
approv octob
valuat novo trade pe premium eu
peer line histori ev/npv vs peer
price rel chart measur perform
omxc close
spot exchang rate
valuat metric
price-to-earnings rel local market
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
novo nordisk a/ denmark-bas compani engag
discoveri develop manufactur market
segment diabet biopharmaceut
profit tax
associ
chang work capit
cash non-cash item
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ
chang net cash/debt
oral sema insulin sale base case
net debt start
chang net debt
net debt end
total equiti liabil
share wtd average mn
ratio valuat
net debt ebitda
grey model pipelin failur weaker oral sema insulin
sale base case
price rel chart measur perform omxc
close
spot exchang rate
chart ada
lilli present data trial three differ titrat regimen
co-agonist tirzepatid slower titrat lower rate primari
gi side effect appear somewhat expect reduct initi
glucos control weight loss
american diabet associ scientif session poster present fria et al poster present june
american diabet associ scientif session poster present fria et al poster present june
figur tirzepatid efficaci weight loss variou titrat
american diabet associ scientif session poster present fria et al poster present june
confid novo establish semaglutid standard-of-car due
combin weight loss blood sugar control enter
market tirzepatid expect strategi high dose ozemp
diabet fulli recruit step trial obes studi
larg subgroup diabet patient within expect supplement
second studi specif diabet expect start shortli run
around time data set read novo expect
acceler approv expect toler issu
seen tirzepatid novo expect weight loss
comment reduct still enrol novo know
baselin popul weight level also highlight novo earli
data tripl therapi later year
rewind data support broader usag
rewind cardiovascular outcom trial trulic show rel reduct
composit mace endpoint non-fat heart attack non-fat stroke
cardiovascular death although non-fat stroke endpoint
confid interv hazard ratio cross
data line prior cv outcom studi although patient includ
rewind lower risk cv event patient popul
repres patient popul seen real-world clinic practic
figur overal hazard ratio seen rewind in-lin expect
meta-analysi prior cardiovascular outcom trial
compon mace
believ rewind data lilli build share voic help grow
market howev believ driver use remain reduct
weight loss rather cv benefit ozemp demonstr
novo updat ada support oral sema
detail data vs jardianc vs victoza
gener expect follow previou top-lin data disclosur via press releas
full cv outcom data present tuesday morn
focu product remain will patient take real world
given nuanc around must taken wait eat
novo price product rel oral agent inject
detail analysi oral sema upgrad note april reiter
sale probabl success oral sema
figur pioneer trial result bodi weight reduct
fx impact sale
sell cost sale
 sale
admin sale
fx impact oper profit
lc dkk donut hole
impact revers prv/sever
lc inc rebound post
prv/sever
cost dkk hedg
cost dkk
op profit tax/net op asset
less major bolt
n/c dkk bought back may
 declin
unchang
move due higher
novo premium/ discount eu
novo premium/ discount global
total diabet obes care
sale
sale
licenc fee op incom
compani mention price
